Tweet
Am J Cardiol
. 2021 Feb 19;S0002-9149(21)00153-3.
doi: 10.1016/j.amjcard.2021.02.009. Online ahead of print.
Impact of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Hypertensive Patients with COVID-19 (COVIDECA Study)
Hazrije Mustafic 1 , Abdallah Fayssoil 2 , Lo?c Josseran 3 , Mounir Ouadahi 2 , Lamiae Grimaldi-Bensouda 4 , Olivier Dubourg 1 , Djillali Annane 5 , Nicolas Mansencal 6
Affiliations
- PMID: 33617818
- DOI: 10.1016/j.amjcard.2021.02.009
Abstract
Effect of angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB) among hypertensive patients with coronavirus disease 2019 (COVID-19) is debated. The aim of the COVIDECA study was to assess the outcome of ACEI and ARB among hypertensive patients presenting with COVID-19.We reviewed from the Assistance Publique-H?pitaux de Parishealthcare record database all patients presenting with confirmed COVID-19 by RT-PCR. We compared hypertensive patients with ACEI or ARB and hypertensive patients without ACEI and ARB. Among 13,521 patients presenting with confirmed COVID-19 by RT-PCR, 2981 hypertensive patients (mean age: 78.4 ? 13.6 years, 1464 men) were included. Outcome of hypertensive patients was similar whatever the use or non-use of ACEI or ARB: admission in ICU (13.4% in patients with ACEI or ARB versus 14.8% in patients without ACEI/ARB, p = 0.35), need of mechanical ventilation (5.5% in patients with ACEI or ARB versus 6.3% in patients without ACEI/ARB, p = 0.45), in-hospital mortality (27.5% in patients with ACEI or ARB versus 26.7% in patients without ACEI/ARB, p = 0.70). In conclusion, the use of ACEI and ARB remains safe and can be maintained in hypertensive patients presenting with COVID-19.
Keywords: Angiotensin II receptor blockers; Angiotensin-converting enzyme inhibitors; COVID-19; Hypertension; outcome.